Why the United States Must Fall in Love with Biotechnology, or Take a Back Seat to China

Episode Summary

Executive Summary: Drew Endy argues synthetic biology is becoming a general-purpose technology that could reshape manufacturing, defense, and medicine, but the U.S. lacks a coherent national strategy and underinvests in foundational tools and standards. He says China’s all-of-nation approach, broad cultural acceptance, and heavy infrastructure spending are positioning it to lead the global bioeconomy unless the U.S. boosts basic research, measurement, and public engagement.

Main Topics: Synthetic biology as a general-purpose technology (Priority: 5/5): Endy frames biology as something that can be encoded in DNA and then grown into medicines, fuels, materials, industrial chemicals, and even components of hardware, expanding biotech far beyond healthcare. China’s all-of-nation biotech strategy (Priority: 5/5): He describes China’s long-term, coordinated push—driven by food security, government support, talent pipelines, and large research institutions—as a major factor behind its biotech rise. U.S. policy gaps and misallocated research funding (Priority: 5/5): Endy argues the U.S. has repeatedly failed to implement a comprehensive bioeconomy strategy and has focused too much on short-term applications instead of foundational capabilities. Biomanufacturing and the ‘bionet’ future (Priority: 4/5): He envisions a distributed biomanufacturing ecosystem with a bio-belt of factories and a bionet that can locally produce needed goods from downloadable DNA instructions. Measurement, standards, and tools as the real leverage points (Priority: 5/5): Endy proposes major public investment in biological measurement and tool-building, especially through NIST and a national biotechnology accelerator, to improve coordination and productivity. Cultural acceptance and making biotechnology personal (Priority: 4/5): He stresses that public enthusiasm and familiarity matter, sharing stories about GMOs, glowing petunias, and student competitions as ways to build trust and excitement. Education and public infrastructure for biotech literacy (Priority: 3/5): Endy advocates for a nationwide network of public labs and library-like spaces, plus programs like iGEM, to make biotechnology accessible and socially normalized.

Key Arguments: Biology should be treated as a general-purpose technology, not just a medical field, because anything encoded in DNA can potentially be manufactured or grown. China’s rise in biotech is the result of sustained, coordinated national effort rather than a sudden breakthrough. Food security is a key driver of China’s willingness to embrace biotechnology aggressively, reducing hesitation around GMOs. The U.S. lost momentum on emerging biotech due to political hesitation, especially around GMO concerns, and lacks a coherent long-term federal strategy. Public money should fund foundational infrastructure—standards, measurement, tools, and platforms—not only near-term disease cures or product development. ARPA-H illustrates a systemic problem: biotechnology funding is often constrained to immediate health outcomes, unlike past investments that enabled the internet and other general-purpose technologies. If the U.S. wants to stay competitive, it should dramatically increase spending on biotech foundations and tool innovation rather than only targeted applications. Cultural adoption matters: when people experience biotech as useful, fun, and personal, political resistance declines and innovation becomes easier to sustain. A national biotech ecosystem should include public labs, standards institutions, and educational pipelines to make the technology broadly legible and usable. China’s growing capability could lead to a dominant biotechnology stack, creating both soft power and strategic dependence for other nations.

Data Points: Global bioeconomy size: about $4 trillion per year - Endy says biotechnology currently accounts for roughly this much global GDP Potential future global bioeconomy size: up to $30 trillion per year - His estimate of what the bioeconomy could grow to as biology becomes a general-purpose technology Current U.S. share of the global bioeconomy: about $1 trillion of $4 trillion - Endy’s rough estimate of the U.S. portion today NSCEB recommended new funding: $15 billion over five years - He cites the National Security Commission on Emerging Biotechnology’s report Endy’s suggested funding level: $30 billion per year for five years - He argues the U.S. should add a zero to current proposals Biodata/biomeasurement proposal: $250 million per year - Endy’s suggested net-new funding for a NIST biomeasurement laboratory Shenzhen institute staffing: 5,000 people total - Endy describes the Shenzhen Institute of Advanced Technology’s scale Shenzhen institute composition: 2,500 staff and 2,500 students/postdocs - He gives the breakdown of the institute’s workforce BGI funding example: $1 billion - Endy cites this as the amount BGI received in Shenzhen in 2010 iGEM participation: 5,000 students a year - He says the biotechnology competition engages this many students annually China iGEM participation: about half - Endy says roughly half of iGEM students are from China

Pivotal Quotes: "anything we learn to encode in DNA, we can grow it." — Drew Endy: Explaining why biotechnology could expand across many industries beyond medicine "whichever nation learns to fall in love with biotechnology first will have a significant competitive advantage." — Drew Endy: Describing why cultural embrace and public enthusiasm matter strategically "the world will increasingly run on China's biotechnology stack." — Drew Endy: Predicting the strategic consequences if the U.S. fails to invest and organize effectively

Implications: The biotech race is shifting from single products to national ecosystems. Countries that invest in standards, tools, and public acceptance will shape manufacturing, health, and security; those that don’t may become dependent on others’ biotech platforms.